Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Appendix B: Drug Characteristics Tables
Characteristics of CD4 Post-Attachment Inhibitor
Last Updated: December 18, 2019; Last Reviewed: December 18, 2019
|Formulation||Dosing Recommendations||Serum Half-Life||Elimination/ Metabolic Pathway||Adverse Events|
||~64 hours||Not well defined||Diarrhea
|Key: IBA = ibalizumab; IV = intravenous|